Collection |

Nature Biotechnology’s academic spinouts 2020

Nature Biotechnology’s annual survey highlights academic startups that are, among other things, designing cytokines, tackling various immune disorders and cancer with T- and B-cell therapies, providing gene therapy using novel delivery methods, and enlisting the microbiome to treat hyperoxaluria and cancer.

As in previous years of our survey, we have focused on R&D-intensive startups spun out from academic institutions. These were first identified as having raised a series A financing in 2020. Our editors then assessed publicly available information about each firm’s research to select those that appear below. (Some firms were selected but not included because they were still in ‘stealth mode’ or declined to be interviewed.) Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel and Laura DeFrancesco report.

News Feature

Cytokines are problematic drugs, but Stanford structural immunologist Chris Garcia has engineered creative solutions that his company will begin testing this year in cancer

News Feature | | Nature Biotechnology